Patent · US Active

Anti-amyloid antibodies

US8268973B2 · kind B2 · utility

4Cited by

9References

18Claims

0Family size

Assignee

Onclave Therapeutics Limited · IE

Inventors

Dale B. Schenk · Burlingame, US
Peter A. Seubert · South San Francisco, US
Jose Saldanha · Ormskirk, GB

Key dates

Filing date	Jul 20, 2011
Grant date	Sep 18, 2012
Priority date	—
Expiry date	Jul 20, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/809
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.